Anker, Stefan D; Khan, Muhammad Shahzeb; Butler, Javed; Ofstad, Anne Pernille; Peil, Barbara; Pfarr, Egon; Doehner, Wolfram; Sattar, Naveed; Coats, Andrew JS; Filippatos, Gerasimos; +4 more... Ferreira, João Pedro; Zannad, Faiez; Pocock, Stuart; Packer, Milton; (2022) Weight change and clinical outcomes in heart failure with reduced ejection fraction: insights from EMPEROR-Reduced. European journal of heart failure, 25 (1). pp. 117-127. ISSN 1388-9842 DOI: https://doi.org/10.1002/ejhf.2728
Permanent Identifier
Use this Digital Object Identifier when citing or linking to this resource.
Abstract
AIMS: Baseline body mass index (BMI) and weight loss promoted by sodium-glucose cotransporter 2 inhibitors may impact outcomes in patients with heart failure with reduced ejection fraction (HFrEF). We assessed in the EMPEROR-Reduced population treated with empagliflozin versus placebo the relationship between baseline BMI, weight loss and effects on the primary (time to first hospitalization for heart failure [HHF] or cardiovascular death) and key secondary outcomes. METHODS AND RESULTS: We categorized patients according to their baseline BMI: <20 kg/m2 (n = 180); 20 to <25 kg/m2 (n = 1038); 25 to <30 kg/m2 (n = 1345); 30 to <35 kg/m2 (n = 774) and ≥35 kg/m2 (n = 393). The treatment effect of empagliflozin on the primary outcome was consistent across all BMI categories (hazard ratios in subgroups 0.66-0.88, interaction trend p = 0.32), as was the effect on total (first plus recurrent) HHF (interaction trend p = 0.31). Empagliflozin reduced the rate of estimated glomerular filtration rate decline consistently across the BMI categories (interaction trend p = 0.67). Overall, incidence rates of any or serious adverse events were comparable between the treatment groups across all BMI categories. A total of 313 (17.4%) patients treated with empagliflozin experienced a weight loss of more than 5% at week 52 versus 230 (12.8%) in placebo. When analysed separately within each treatment group, presence of weight loss was similarly associated with an increased risk of all-cause mortality. CONCLUSION: The benefits of empagliflozin versus placebo were consistently present across all BMI categories in HFrEF patients. Weight loss was associated with higher risk of all-cause mortality, regardless of treatment group.
Item Type | Article |
---|---|
Faculty and Department | Faculty of Epidemiology and Population Health > Dept of Medical Statistics |
PubMed ID | 36325584 |
Elements ID | 196198 |
Official URL | http://dx.doi.org/10.1002/ejhf.2728 |
Download
Filename: Anker_etal_2022_Weight-Change-and-Clinical-Outcomes.pdf
Description: This is an author accepted manuscript version of an article accepted for publication and following peer review. Please be aware that minor differences may exist between this version and the final version if you wish to cite from it.
Licence: Creative Commons: Attribution-Noncommercial-No Derivative Works 3.0
Download